Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESUNET: Sunitinib Rechallenge in Metastatic Pancreatic Neuroendocrine Tumors
2015-005774-37Phase 2Completed
- Sponsor
- Spanish Group of Neuroendocrine Tumors
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in islet cell tumor, sponsored by Spanish Group of Neuroendocrine Tumors. Primary endpoint: 6-month progression-free survival. Started Feb 2016; status: completed.
02
Drugs
sunitinib
03
Conditions
islet cell tumor
Beyond the preview
Go deeper on 2015-005774-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005774-37.